Moleculin Biotech, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2016. Moleculin was organized in July 2015 and is a preclinical and clinical-stage oncology drug developer. It reported no revenue and no prior-year comparable quarter; consequently, year-over-year comparisons are unavailable.
Financial results and position
| Metric | March 31, 2016 / Q1 2016 | Comparison |
|---|---|---|
| Revenue | $0 | No comparable quarter presented |
| Research and development expense | $15,000 | Primarily accrued license fees |
| General and administrative expense | $305,571 | Primarily IPO-related professional fees and CFO compensation |
| Total operating expenses | $320,571 | No comparable quarter presented |
| Interest expense | $11,670 | Accrued on 8% convertible notes |
| Net loss | $332,241 | Basic and diluted loss per share: $0.05 |
| Cash and cash equivalents | $259,663 | $28,091 at December 31, 2015 |
| Total liabilities | $978,003 | $772,790 at December 31, 2015 |
| Convertible notes payable | $615,000 | $450,000 at December 31, 2015 |
| Stockholders’ deficit | $688,340 | $744,699 at December 31, 2015 |
Operating cash use was $289,927; investing cash use was $30,000, reflecting a loan to Moleculin, LLC; financing provided $551,499 from stock sales and convertible notes. Cash increased by $231,572. The filing reports a $688,340 working-capital deficit. Profitability and operating margins are not meaningful because the company had no revenue.
Material developments and outlook
- Programs: The lead candidate is liposomal Annamycin for relapsed or refractory AML. Its former IND had been terminated after a prior developer ceased activity; the company intended to seek a new IND and pursue a Phase II trial. Other programs are the WP1066 and WP1122 portfolios, licensed from MD Anderson.
- Financing and merger after quarter-end: On May 31, 2016, the company completed an IPO of 1,540,026 shares at $6.00 per share. The filing gives conflicting net-proceeds figures: $8,459,493 in one section and $8,317,594 in another. It also reports subsequent private share sales totaling $316,389 through May 2. On May 2, Moleculin, LLC merged into the company; approximately 706,000 shares went to its equity holders and approximately 294,000 to its noteholders. The company assumed liabilities, including $306,176 payable to MD Anderson.
- Liquidity outlook: Management said cash at March 31, subsequent share-sale proceeds, and IPO proceeds were expected to fund planned operations for at least 12 months from June 1, 2016, including the planned Annamycin Phase II trial. The company expected to require further financing and warned it may be unavailable on acceptable terms or at all.
- Going concern: The filing identifies substantial doubt based on accumulated losses of $1,080,601, a working-capital deficit, and no operating revenue. The subsequent IPO is a significant financing event, but does not eliminate the development and future-funding risks.
- Other risks and commitments: Drug development, clinical and regulatory outcomes, third-party manufacturing and research providers, financing needs, and license obligations are key risks. WP1122 licensing includes maintenance fees, milestone payments, royalties, and potential termination conditions. Annamycin substance was no longer covered by existing patent protection; intended new patent applications and possible orphan or other exclusivity were not assured.
- Controls and legal matters: Management concluded disclosure controls were not effective as of March 31, 2016; no material change in internal control was reported. The company reported no legal proceedings.
Important facts for investors to verify
- Reconcile the two different reported IPO net-proceeds amounts and confirm the final cash available after offering expenses and subsequent obligations.
- Review post-merger financial statements and purchase-price allocation; the filing said the approximately $6 million allocation was still being determined.
- Confirm the status, timing, funding, and regulatory path for the planned Annamycin IND and Phase II trial, and progress of the WP1066 and WP1122 programs.
- Assess dilution and conversion terms for the $615,000 of notes outstanding at quarter-end, including accrued interest, ownership limits, and trading restrictions; the filing describes conversion into shares following the IPO.
- Monitor liquidity, MD Anderson license payments and milestones, and remediation of ineffective disclosure controls.